A newborn with a large NTRK fusion positive infantile fibrosarcoma successfully treated with larotrectinib

Area of Science:

• Pediatric Oncology
• Molecular Oncology

Background:

• Infantile fibrosarcoma (IFS) is a rare pediatric malignancy.
• Surgical resection is the primary curative treatment, but is not always feasible.
• Many IFS cases harbor neurotrophic receptor tyrosine kinase (NTRK) gene fusions.

Observation:

• A case of infantile fibrosarcoma in a newborn is presented.
• The patient was treated with larotrectinib, a tropomyosin receptor kinase (TRK) inhibitor.
• Larotrectinib is known for its safety and efficacy in young children.

Findings:

• The newborn with infantile fibrosarcoma experienced a rapid clinical and radiographic response to larotrectinib.
• This response demonstrates the drug's effectiveness in a neonatal patient.
• The treatment was well-tolerated by the infant.

Implications:

• Larotrectinib shows promise as a treatment option for infantile fibrosarcoma in newborns.
• Targeted therapy with TRK inhibitors may be a viable strategy for neonatal cancers.
• Further investigation into larotrectinib for neonatal IFS is warranted.